ChromaDex (NASDAQ:CDXC) Earns Buy Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of ChromaDex (NASDAQ:CDXC) in a note issued to investors on Thursday. The firm set a “buy” rating on the stock.

CDXC has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of ChromaDex in a report on Monday, March 17th. LADENBURG THALM/SH SH raised their target price on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

ChromaDex Stock Performance

The firm’s 50 day moving average is $6.16 and its two-hundred day moving average is $5.44. ChromaDex has a one year low of $2.31 and a one year high of $9.18. The firm has a market cap of $611.50 million, a PE ratio of 787.29 and a beta of 2.21.

Hedge Funds Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. USA Financial Formulas acquired a new stake in ChromaDex during the 4th quarter worth approximately $25,000. State of Wyoming acquired a new position in ChromaDex during the fourth quarter valued at approximately $39,000. Mercer Global Advisors Inc. ADV acquired a new position in ChromaDex during the fourth quarter worth $53,000. Truist Financial Corp bought a new stake in shares of ChromaDex in the 4th quarter valued at about $54,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of ChromaDex during the 4th quarter worth approximately $67,000. 15.41% of the stock is owned by institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.